Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review

CONCLUSIONS: According to low-quality evidence mainly from cohort studies and case series, approximately one half of patients with CD and UC/IBD-U achieved remission at 1 year. Ustekinumab has a reasonable safety profile and dose optimization is frequently required. Data on the long-term benefit and high-quality evidence are still needed.PMID:37528211 | DOI:10.1007/s40272-023-00586-7
Source: Paediatric Drugs - Category: Pediatrics Authors: Source Type: research